Loading clinical trials...
Loading clinical trials...
A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Adult and Adolescent Participants With Sickle Cell Disease
Conditions
Interventions
Osivelotor
Locations
49
United States
Smilow Cancer Hospital
New Haven, Connecticut, United States
Edward Jenner Research Group Center LLC
Plantation, Florida, United States
Pediatric Hematology / Oncology a division of Kidz Medical services
West Palm Beach, Florida, United States
St. Mary's Medical Center
West Palm Beach, Florida, United States
Alpha Clinical Research Georgia
Dunwoody, Georgia, United States
Sonar Clinical Research
Riverdale, Georgia, United States
Start Date
September 22, 2022
Primary Completion Date
December 30, 2030
Completion Date
December 31, 2032
Last Updated
March 20, 2026
NCT06612268
NCT06820515
NCT07392216
NCT04416178
NCT05359991
NCT05170412
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions